AbbVie Inc. / Ichnos Glenmark Innovation (IGI)

Relapsed/refractory multiple myeloma

36K US cases/yr · $32.0B Global multiple myeloma market (2030 projected) · ~60-70% Triple-class refractory MM 5-year mortality rate

Disease Overview

Multiple myeloma (MM) is a plasma cell malignancy characterized by monoclonal immunoglobulin production, bone destruction, renal impairment, anemia, and hypercalcemia. Despite major therapeutic advances - proteasome inhibitors, IMiDs, anti-CD38 antibodies, BCMA-directed CAR-T and bispecifics - nearly all patients eventually relapse or become refractory (R/R MM), and median survival after triple-class refractoriness is approximately 12-18 months. The R/R MM competitive battleground has moved rapidly from single-target agents (anti-CD38: daratumumab/Darzalex, isatuximab/Sarclisa; BCMA CAR-T: idecabtagene vicleucel/Abecma, ciltacabtagene autoleucel/Carvykti; BCMA bispecifics: teclistamab/Tecvayli, elranatamab/Elrexfio; GPRC5D bispecific: talquetamab/Talvey) toward sequential and multi-target strategies to overcome antigen escape and T-cell exhaustion. AbbVie's thesis in licensing ISB 2001 from Ichnos Glenmark Innovation (IGI) for up to $1.925B is that a first-in-class CD38 x BCMA x CD3 trispecific T-cell engager delivers simultaneous dual-antigen targeting - collapsing the key escape mechanisms that limit the durability of single-target bispecifics and CAR-Ts - with off-the-shelf convenience.

Competitive Landscape

The R/R MM competitive MOA landscape is stratified across four tiers. BCMA-directed CAR-T is commercial: Bristol Myers Squibb's idecabtagene vicleucel (Abecma), Johnson & Johnson/Legend Biotech's ciltacabtagene autoleucel (Carvykti). BCMA and GPRC5D bispecific T-cell engagers are established: Johnson & Johnson's teclistamab (Tecvayli, BCMAxCD3), Pfizer's elranatamab (Elrexfio, BCMAxCD3), Johnson & Johnson's talquetamab (Talvey, GPRC5DxCD3), and Regeneron's linvoseltamab (Lynozyfic). Anti-CD38 monoclonal antibodies are backbone therapy: Johnson & Johnson's daratumumab (Darzalex/Darzalex Faspro), Sanofi's isatuximab (Sarclisa). Antibody-drug conjugates include GSK's belantamab mafodotin (Blenrep, relaunched post-DREAMM-7). Trispecific T-cell engagers - the space ISB 2001 enters - include Pfizer's ABBV-383 (BCMAxCD3, now AbbVie via ownership chain), Regeneron's odronextamab in lymphoma with myeloma crossover, Harpoon Therapeutics' (Merck) HPN217 (BCMAxCD3xAlbumin), and Janssen's JNJ-79635322 (BCMAxGPRC5DxCD3). ISB 2001's CD38 x BCMA x CD3 trispecific differentiation is dual tumor-antigen targeting in one molecule, which AbbVie positions as a durability-and-resistance-overcoming step beyond single-target bispecifics.